Nervous Disorder TRIZ Cases
- Mutated tPA Clears Neurotoxins Without Hemorrhage
Removing serine protease activity from tPA prevents intracerebral hemorrhage while maintaining the ability to clear glutamate and lactate.
- Fusion Proteins Recruiting Hsp70 to Reduce Tau Aggregation
Fusion proteins recruit the Hsp70 chaperone mechanism to reduce tau-mediated protein aggregation, addressing neuronal degeneration in Alzheimer's disease.
- Deuterated Dextromethorphan and Quinidine for Alzheimer Agitation
Combining deuterated dextromethorphan with quinidine reduces agitation symptoms in Alzheimer patients, addressing the lack of approved treatments.
- CtBP Inhibitory Compounds for Traumatic Brain Injury Treatment
Targeting C-terminal binding proteins with inhibitory agents alleviates traumatic brain injury symptoms by suppressing neuroinflammatory pathways.
- Anti-Flt-1 Antibodies for Duchenne Muscular Dystrophy Treatment
Anti-Flt-1 antibodies block VEGF binding to Flt-1 receptors, increasing available VEGF for other receptors to treat Duchenne muscular dystrophy.
- Allele-Specific Silencing Agents Targeting HTT Polymorphisms
Targeting flanking sequence polymorphisms enables allele-specific silencing of mutant huntingtin, avoiding embryonic lethality from constitutive knockout.
- Synergistic CBD and Hypothermia Neuroprotection for NHIE
Merging cannabidiol with hypothermia addresses partial protection limits by reducing brain damage in neonatal encephalopathy.
- Crystalline Forms of Compound 3 for Oral Complement Factor D Inhibition
Crystalline forms of Compound 3 resolve the trade-off between therapeutic efficacy and intravenous injection complexity by enabling stable oral administration.
- Substituted Phenyl-Propenal Compound for Neurodegenerative Disorder Treatment
ASC-JM17 addresses insufficient therapeutic efficacy of natural products by suppressing polyQ aggregation and improving mitochondrial function.
- Mimotope Peptides Targeting Truncated Amyloid Beta
Mimotope peptides induce specific antibodies against truncated amyloid forms, avoiding autoimmune side effects from full-length APP targeting.
- Donepezil Memantine Composition Controlled Release
A pharmaceutical composition combines donepezil and memantine in a single tablet using pH-dependent polymeric substances for controlled drug release.
- Sulfamate Derivative Compounds for Pain Relief
Sulfamate derivatives minimize adverse side effects while maintaining potent pain relief via structural parameter optimization.
- Kinase Inhibitor Compounds Targeting Drug-Resistant ROS1, NTRK, and ALK Mutations
Novel kinase inhibitor compounds overcome drug resistance in ROS1, NTRK, and ALK mutations via targeted structural modifications.
- APC Mutants with Reduced Bleeding Risk
Specific amino acid mutations in recombinant activated protein C reduce anticoagulant activity while maintaining cytoprotective effects, lowering bleeding risk.
- Targeting Aggregated Peptides for Traumatic Brain Injury Treatment
Administering specific antibodies to reduce toxic peptide aggregates in the brain.
- MDMA Prodrugs for Controlled Release and Reduced Abuse
N-acetyll lysine conjugates slow MDMA release, reducing anxiety and abuse liability.
- Peptide Immunoadsorption for Adrenoreceptor Autoantibody Neutralization
Immunoadsorption using specific peptides removes autoantibodies from plasma, reducing gamma-secretase activity and beta-amyloid release in cerebral cells.